News Sort by Year All Years 2023 (7) 2023 (7) 2022 (29) 2021 (17) 2020 (19) 2019 (12) 2018 (18) 2017 (19) 2016 (32) 2015 (43) 2014 (50) 2013 (32) 2012 (17) Search March 20, 2023 Theriva Biologics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results March 20, 2023 Theriva Biologics realizará una teleconferencia y retransmisión por Internet para comentar los aspectos operativos más destacados y los resultados financieros del cuarto trimestre y del ejercicio 2022 February 16, 2023 Theriva Biologics anuncia la presentación de los datos de seguridad de uso y farmacocinética de la cohorte 1 del ensayo clínico de fase 1b/2a de SYN-004 (ribaxamasa) en receptores de trasplantes alogénicos de células hematopoyéticas February 16, 2023 Theriva Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients January 17, 2023 Theriva Biologics Announces First Patient Dosed in VIRAGE, a Phase 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma January 17, 2023 Theriva Biologics to Participate in the B. Riley Securities 3rd Annual Oncology Conference January 9, 2023 Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors December 1, 2022 Theriva Biologics to Participate in Upcoming Investor Conferences November 10, 2022 Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results November 10, 2022 Theriva Biologics Reports Third Quarter 2022 Operational Highlights and Financial Results
